These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 31692920)

  • 41. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2019 Jul; 15(7):693-700. PubMed ID: 30987474
    [No Abstract]   [Full Text] [Related]  

  • 42. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. JAK Inhibitors: What Is New?
    Reddy V; Cohen S
    Curr Rheumatol Rep; 2020 Jul; 22(9):50. PubMed ID: 32700001
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review.
    Skouvaklidou E; Deligeorgakis D; Skalkou A; Skepastianos V; Tsafis K; Papadimitriou E; Pagkopoulou E; Avgerou P; Mytilinaiou MG; Tzitiridou-Chatzopoulou M; Kougkas N; Adamichou C
    Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):1-9. PubMed ID: 38756936
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
    Sung YK; Lee YH
    J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Comprehensive Overview of Globally Approved JAK Inhibitors.
    Shawky AM; Almalki FA; Abdalla AN; Abdelazeem AH; Gouda AM
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631587
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Upadacitinib tartrate in rheumatoid arthritis.
    Stamatis P; Bogdanos DP; Sakkas LI
    Drugs Today (Barc); 2020 Nov; 56(11):723-732. PubMed ID: 33332480
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
    Choy EHS; Miceli-Richard C; González-Gay MA; Sinigaglia L; Schlichting DE; Meszaros G; de la Torre I; Schulze-Koops H
    Clin Exp Rheumatol; 2019; 37(4):694-704. PubMed ID: 30767864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
    Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis.
    Srivastava S; Rasool M
    Life Sci; 2022 Jun; 298():120516. PubMed ID: 35367240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Filgotinib as rheumatoid arthritis therapy.
    Becciolini A; Di Donato E; Santilli D; Lucchini G; Mozzani F; Riva M; Ariani A
    Drugs Today (Barc); 2021 Sep; 57(9):543-550. PubMed ID: 34586102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.
    Meyer DM; Jesson MI; Li X; Elrick MM; Funckes-Shippy CL; Warner JD; Gross CJ; Dowty ME; Ramaiah SK; Hirsch JL; Saabye MJ; Barks JL; Kishore N; Morris DL
    J Inflamm (Lond); 2010 Aug; 7():41. PubMed ID: 20701804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
    Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
    Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials.
    Tarrant JM; Galien R; Li W; Goyal L; Pan Y; Hawtin R; Zhang W; Van der Aa A; Taylor PC
    Rheumatol Ther; 2020 Mar; 7(1):173-190. PubMed ID: 31912462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
    Taylor PC
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.
    Cutolo M
    Ther Adv Musculoskelet Dis; 2013 Feb; 5(1):3-11. PubMed ID: 23515130
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.